KAT8-mediated PCK2 acetylation at K491 impairs lysosomal degradation to elevate PCK2 expression in sorafenib-resistant liver tumor cells, while PCK2 silencing in sorafenib-resistant cells could reduce tumor resistance. Here, PCK2 is linked to neoplasm.